載入中
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
收盤時
US$8.74
+US$0.40 · +4.80%
盤後
US$8.73
−US$0.01 · -0.11%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
日內區間
目前US$8.74
52週區間
目前US$8.74
盤中時間採用ET。市場資料可能有所延遲。
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
日內區間
目前US$8.74
52週區間
目前US$8.74
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5373.7萬 USD | — | −665.1萬 USD | 665.1萬 USD | — |
| 毛利 | 5373.7萬 USD | — | −665.1萬 USD | 665.1萬 USD | — |
| 研究與開發 | 1915.6萬 USD | 4814.3萬 USD | 3172.9萬 USD | 3581.4萬 USD | 2992.9萬 USD |
| 銷售、一般及管理費用 | 1767.9萬 USD | 1795.9萬 USD | 987.5萬 USD | 1006.2萬 USD | 676.4萬 USD |
| 營業費用 | 3683.5萬 USD | 6610.2萬 USD | 4160.4萬 USD | 4587.6萬 USD | 3669.3萬 USD |
| 利息收入 | 220萬 USD | 390萬 USD | — | — | — |
| 利息支出 | 110萬 USD | 110萬 USD | — | — | — |
| 折舊和攤銷 | 39.1萬 USD | 48.7萬 USD | 49.9萬 USD | 37萬 USD | 954.4萬 USD |
| 營業利益 | 1690.2萬 USD | −6610.2萬 USD | −4825.5萬 USD | −3922.5萬 USD | −3669.3萬 USD |
| 淨利 | 2982.1萬 USD | −4773.3萬 USD | −5374.3萬 USD | −4280.9萬 USD | −3756.4萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV441.18萬0.01%308.51億 USD0.25%US$119.94+0.25%
First Trust Dow Jones Select MicroCap Index FundFDM74.34萬0.28%2.61億 USD0.65%US$88.895+0.50%
Dimensional - US Small Cap ETFDFAS34.11萬0.00%338.69億 USD0.31%US$78.17-0.23%
Dimensional - US Targeted Value ETFDFAT27.76萬0.00%301.22億 USD0.33%US$67.42+0.22%
iShares Micro-Cap ETFIWC25.23萬0.02%13.17億 USD0.60%US$181.66-0.73%
Avantis U.S. Small Cap Equity ETFAVSC23.73萬0.01%30.82億 USD0.25%US$69.97-0.01%
Avantis U.S. Equity ETFAVUS14.89萬—148.63億 USD0.15%US$130.54+0.02%
Hartford Multifactor Small Cap ETFROSC9.93萬0.21%4747.96萬 USD0.34%US$54.4172+0.23%Avantis U.S. Small Cap Value ETFAVUVFirst Trust Dow Jones Select MicroCap Index FundFDMDimensional - US Small Cap ETFDFASDimensional - US Targeted Value ETFDFATiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCAvantis U.S. Equity ETFAVUSHartford Multifactor Small Cap ETFROSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
